Display options
Cite
Kanda T, Yasui S, Nakamura M, et al. Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget. 2018;9(14):11631-11637doi: 10.18632/oncotarget.24391.
Kanda, T., Yasui, S., Nakamura, M., Nakamoto, S., Takahashi, K., Wu, S., Sasaki, R., Haga, Y., Ogasawara, S., Saito, T., Kobayashi, K., Kiyono, S., Ooka, Y., Suzuki, E., Chiba, T., Maruyama, H., Imazeki, F., Moriyama, M., & Kato, N. (2018). Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget, 9(14), 11631-11637. https://doi.org/10.18632/oncotarget.24391
Kanda, Tatsuo, et al. "Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis." Oncotarget vol. 9,14 (2018): 11631-11637. doi: https://doi.org/10.18632/oncotarget.24391
Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Imazeki F, Moriyama M, Kato N. Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget. 2018 Feb 03;9(14):11631-11637. doi: 10.18632/oncotarget.24391. eCollection 2018 Feb 20. PMID: 29545925; PMCID: PMC5837765.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Feb 03;9(14):11631-11637. doi: 10.18632/oncotarget.24391. eCollection 2018 Feb 20.

Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis.

Oncotarget

Tatsuo Kanda, Shin Yasui, Masato Nakamura, Shingo Nakamoto, Koji Takahashi, Shuang Wu, Reina Sasaki, Yuki Haga, Sadahisa Ogasawara, Tomoko Saito, Kazufumi Kobayashi, Soichiro Kiyono, Yoshihiko Ooka, Eiichiro Suzuki, Tetsuhiro Chiba, Hitoshi Maruyama, Fumio Imazeki, Mitsuhiko Moriyama, Naoya Kato

Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo 173-8610, Japan.
  2. Department of Gastroenterology, Chiba University, Graduate School of Medicine, Chiba 260-8670, Japan.

PMID: 29545925 PMCID: PMC5837765 DOI: 10.18632/oncotarget.24391

Abstract

BACKGROUND: Interferon-free treatment can achieve higher sustained virological response (SVR) rates, even in patients in whom hepatitis C virus (HCV) could not be eradicated in the interferon treatment era. Immune restoration in the liver is occasionally associated with HCV infection. We examined the safety and effects of interferon-free regimens on HCV patients with autoimmune liver diseases.

RESULTS: All 7 HCV patients with autoimmune hepatitis (AIH) completed treatment and achieved SVR. Three patients took prednisolone (PSL) at baseline, and 3 did not take PSL during interferon-free treatment. In one HCV patient with AIH and cirrhosis, PSL were not administered at baseline, but she needed to take 40 mg/day PSL at week 8 for liver dysfunction. She also complained back pain and was diagnosed with vasospastic angina by coronary angiography at week 11. However, she completed interferon-free treatment. All 5 HCV patients with primary biliary cholangitis (PBC) completed treatment and achieved SVR. Three of these HCV patients with PBC were treated with UDCA during interferon-free treatment.

CONCLUSIONS: Interferon-free regimens could result in higher SVR rates in HCV patients with autoimmune liver diseases. As interferon-free treatment for HCV may have an effect on hepatic immunity and activity of the autoimmune liver diseases, careful attention should be paid to unexpected adverse events in their treatments.

METHODS: Total 12 patients with HCV and autoimmune liver diseases [7 AIH and PBC], who were treated with interferon-free regimens, were retrospectively analyzed.

Keywords: autoimmune hepatitis; direct-acting antivirals; hepatitis C virus; primary biliary cholangitis; sustained virological response

Conflict of interest statement

CONFLICTS OF INTEREST Tatsuo Kanda received research grants from AbbVie, MSD, Sysmex and Chugai Pharmaceutical. Naoya Kato received grants from AbbVie, MSD, Sysmex, Chugai Pharmaceutical, Gilead Scien

References

  1. J Viral Hepat. 2015 Dec;22(12):983-91 - PubMed
  2. PLoS One. 2013 Oct 10;8(10):e75613 - PubMed
  3. J Hepatol. 1999 Nov;31(5):929-38 - PubMed
  4. Dig Dis Sci. 1995 Oct;40(10):2113-6 - PubMed
  5. Dig Dis Sci. 1995 Jun;40(6):1226-30 - PubMed
  6. Biology (Basel). 2017 May 09;6(2):null - PubMed
  7. Hepatol Int. 2010 Aug 19;4(3):548-61 - PubMed
  8. Expert Opin Drug Saf. 2017 Jun;16(6):651-672 - PubMed
  9. Hepatology. 2015 Nov;62(5):1620-2 - PubMed
  10. J Hepatol. 2014 Nov;61(1 Suppl):S58-68 - PubMed
  11. Gastroenterology. 1992 Apr;102(4 Pt 1):1406-8 - PubMed
  12. J Viral Hepat. 2017 Nov 29;:null - PubMed
  13. Ann Hepatol. 2013 Jan-2014 Feb;13(1):127-35 - PubMed
  14. Lancet. 1996 Jan 13;347(8994):92-3 - PubMed
  15. Int J Mol Sci. 2017 Apr 25;18(5):null - PubMed
  16. Transplantation. 2017 May;101(5):904-909 - PubMed
  17. Intern Med. 2017;56(7):787-790 - PubMed
  18. Hepatol Int. 2017 Jan;11(1):38-44 - PubMed
  19. J Hepatol. 1997 May;26(5):992-1000 - PubMed
  20. Hepatology. 2017 Sep 16;:null - PubMed
  21. J Gastroenterol. 2017 May;52(5):631-640 - PubMed
  22. J Gastroenterol. 2003;38(6):573-8 - PubMed
  23. Int J Med Sci. 2016 May 12;13(6):418-23 - PubMed
  24. Clin J Gastroenterol. 2016 Jun;9(3):156-9 - PubMed
  25. Hepatology. 2008 Jul;48(1):169-76 - PubMed
  26. World J Hepatol. 2013 Oct 27;5(10):577-83 - PubMed
  27. Hepatol Int. 2012 Apr;6(2):409-35 - PubMed

Publication Types